American Oriental Bioengineering, Inc.
AOBI · OTC
12/31/2012 | 12/31/2011 | 12/31/2010 | 12/31/2009 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | -0.04 | 0.03 |
| FCF Yield | -498.79% | -189.86% | 4.35% | 23.42% |
| EV / EBITDA | -1.89 | -1.52 | 1.75 | 1.72 |
| Quality | ||||
| ROIC | -13.88% | -0.68% | 3.18% | 8.19% |
| Gross Margin | 30.57% | 46.90% | 51.56% | 56.32% |
| Cash Conversion Ratio | 0.78 | -0.44 | 0.49 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | -22.02% | -10.45% | 4.95% | 22.66% |
| Free Cash Flow Growth | -264.46% | -1,120.65% | -90.39% | 121.40% |
| Safety | ||||
| Net Debt / EBITDA | -1.53 | -1.31 | 0.68 | 0.53 |
| Interest Coverage | -9.42 | -0.54 | 5.15 | 10.23 |
| Efficiency | ||||
| Inventory Turnover | 4.90 | 5.98 | 11.70 | 12.92 |
| Cash Conversion Cycle | 161.00 | 159.91 | 99.63 | 77.98 |